Sharepoint Solutions
PRODUCTS
-
A quick overview of this industry-changing technology as well as the newer Cas9 variants that expand its use.
-
Streamline your Trial Master File (TMF) documentation and integrate with study sites to accelerate trial timelines.
Other eTMFs promise ease of use and seamless integration with the sites eISF, but they can’t deliver 100% adoption.
-
The TWIST™ Mini Liposome Extruder System is an all-inclusive modular liposome extrusion system. The intuitive design allows novice and expert users the ability to create liposome particles ranging from 50 nm to 10 um in diameter. With the heat block and extruder base, users have extended liposome creation capabilities and an easy, ergonomic set up. The TWIST™ System is the perfect solution for small scale R&D and liposome exploration projects.
-
Go from assay to insights quickly and reliably with ImageXpress imaging systems and IN Carta software.
-
25 years of Providing World-Class Medical Information Services.
WHITE PAPERS AND CASE STUDIES
-
Flexible Integrations To Reduce Risks And Increase Efficiencies
Learn how a trial team kept the blind of central lab samples and patient treatment across a Phase III and extension trial, whilst optimizing the supply chain.
-
Can Your Biopharma Team Keep Unplanned Downtime At Bay?
Learn how teams reduce downtime, strengthen compliance, and respond quickly to equipment issues through proactive maintenance, smart spare parts planning, and digital troubleshooting tools.
-
Project Orbis Drug Registration 2025
Project Orbis helps streamline the review and approval of oncology medicinal products through international regulatory collaboration. Learn how this framework can accelerate your regulatory strategy.
-
Relieving The Strain Of Publishing During Regulatory Registration
Go inside how an expertly handled NDA submission for a biopharma company ensured timely FDA approval despite challenges.
-
Evansville Water & Sewer Utility: 4 Tactics For Managing & Organizing Vertical Assets
EWSU, serving 65,000 customers, revamped its vertical asset tracking with POWER Engineers to enhance maintenance workflows. Here's how they optimized their processes.
-
Performance Dashboards Development
Learn about a biotech company's successful implementation of a two-level KPI dashboard system. This enhanced performance monitoring, aligned departmental goals, and strengthened team communication.
-
The Effect Of Conventional Cooling Versus Controlled Ice Nucleation On Primary Drying Time
See how controlled ice nucleation shortens lyophilization cycles, supports higher drying temperatures, and reduces complexity for amorphous and mixed formulations without sacrificing quality.
-
NDA Success Strategy: Using Non-US Clinical Data In An NDA Submission
A sponsor acquiring a therapeutic asset from an overseas company sought assistance when including foreign clinical trial dat,a generated outside a U.S. IND, in a New Drug Application (NDA).
-
Pioneering The End-To-End Decentralized Trial Experience
This collaboration highlights the potential of decentralized clinical trials (DCTs) to transform trial execution, as well as offering a replicable model for future research.
-
Early-Stage Development In Rare Pediatric Oncology
Learn about the strategic approach a biotechnology company utilized to address significant hurdles in launching a Phase 1 clinical trial for a novel therapy targeting a rare pediatric cancer.
-
Inspecting On The Edge — Understanding Punch Tip Wear
Why is a horizontal optical comparator highly recommended for tablet manufacturers as a measuring tool for punch tip inspection, and what strategies can be used to detect, reduce, and prevent tip wear?
-
The Benefits Of End-To-End Formulation And Fill/Finish Of Biologics
Proper formulation development has a huge impact on whether a technology transfer to clinical phase fill/finish is successful. Review the challenges of transitioning a promising drug candidate.
NEWS
-
Axim Biotechnologies Files Pre-Submission With FDA For CLIA Waiver Pathway On Lactoferrin Point-Of-Care Diagnostic Test6/24/2025
Axim Biotechnologies, Inc. a leading developer of rapid diagnostic testing for ocular and systemic conditions, today announced that it has filed a Pre-Submission (Pre-Sub Q) with the U.S. Food and Drug Administration (FDA) as the first formal step in seeking a Clinical Laboratory Improvement Amendments (CLIA) Waiver for its rapid, point-of-care Lactoferrin diagnostic test (TearScan Lf).
-
Greenwater Services Pilot Achieves 91.5% Reduction In Total Coliform Bacteria In Tijuana River Project3/17/2026
Greenwater Services, a water technology company specializing in environmentally safe water treatment and purification technologies, announced that its five-week pilot project on the Tijuana River achieved an average 91.5% reduction in total coliform bacteria on treatment days, significantly exceeding the project’s initial 15-20% performance objectives.
-
Securing Water Systems Against Cyber-Threats: Idaho Leads With Cyber-Informed Engineering3/6/2025
When it comes to cybersecurity research, the Idaho National Laboratory (INL) and Idaho have a relationship that dates back to the 1990s and was hallmarked in 2019 with the opening of the state-funded Cybercore Integration Center on INL’s Research and Education Campus in Idaho Falls.
-
CSU And EPA Partner To Expand Water Data Access10/2/2025
The Radical Open Science Syndicate (ROSS) — a watershed data science lab in the Warner College of Natural Resources — partnered with the U.S. Environmental Protection Agency to improve water data access through Tools for Automated Data Analysis, or TADA, a toolkit empowering water resource managers to use the data they collect.
-
Energy Department Slashes 47 Burdensome And Costly Regulations, Delivering First Milestone In America's Biggest Deregulatory Effort5/12/2025
The U.S. Department of Energy (DOE) today announced the first step in the Energy Department’s largest deregulatory effort in history, proposing the elimination or reduction of 47 regulations that are driving up costs and lowering quality of life for the American people.